Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results

Key Points

• Theravance Biopharma reported a quarterly EPS of $1.08, significantly exceeding the consensus estimate of ($0.12).
• Shares of Theravance Biopharma saw a 4.6% increase on the trading day, reaching $11.92.
• Wall Street analysts have mixed views on the stock, with ratings ranging from "downgraded to hold" to a "strong-buy" rating with a $24 target price.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $1.20, Zacks reports. Theravance Biopharma had a negative return on equity of 32.37% and a negative net margin of 89.38%.

Theravance Biopharma Stock Up 4.6%

Shares of NASDAQ TBPH traded up $0.52 during trading hours on Tuesday, hitting $11.92. The company had a trading volume of 587,322 shares, compared to its average volume of 250,871. Theravance Biopharma has a 1-year low of $7.88 and a 1-year high of $11.99. The stock has a market capitalization of $596 million, a P/E ratio of -10.10 and a beta of 0.01. The firm's 50 day moving average is $11.07 and its 200-day moving average is $9.91.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on TBPH. Wall Street Zen downgraded Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. Jones Trading raised Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price for the company in a research note on Tuesday, June 17th. Finally, BTIG Research upped their price objective on Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, June 27th.

Insider Activity

In other news, SVP Rhonda Farnum sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $11.39, for a total value of $113,900.00. Following the completion of the sale, the senior vice president directly owned 326,918 shares of the company's stock, valued at $3,723,596.02. This trade represents a 2.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold 44,000 shares of company stock valued at $491,800 over the last ninety days. Company insiders own 6.90% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC increased its position in Theravance Biopharma by 169.2% during the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock worth $1,258,000 after buying an additional 88,540 shares during the period. American Century Companies Inc. increased its stake in Theravance Biopharma by 6.8% during the 2nd quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company's stock worth $1,009,000 after acquiring an additional 5,794 shares during the period. Creative Planning bought a new position in Theravance Biopharma during the 2nd quarter worth $139,000. Finally, AQR Capital Management LLC bought a new position in Theravance Biopharma during the 1st quarter worth $101,000. Institutional investors own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.